Abstract: For example, a wireless communication device may be configured to determine a Concurrent Multiple Band (CMB) routing scheme based on Quality of Service (QoS) requirement information and network condition information, the CMB routing scheme to route a plurality of application streams to a plurality of radios of the wireless communication device for wireless communication over a plurality of wireless communication bands, the plurality of application streams corresponding to one or more applications to be executed by the wireless communication device; and to route the plurality of application streams to the plurality of radios by determining, based on the CMB routing scheme, to which radio of the plurality of radios to route the application stream of the plurality of application streams.

Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.

Abstract: The instant application provides biomarkers for the identification of chemosensitivity in patient having cancer, in a particular embodiment the invention provides MST for the identification of chemosensitivity in breast cancer patient, wherein a reduced expression of XIST in the breast cancer cells of the patient indicates that the breast cancer stem cells in the patient may be successfully treated with HDAC inhibitor.

Abstract: An in vitro method for diagnosing a breast cancer from the luminal-B subtype in a female, includes the steps of analyzing a biological sample from the female by (i) determining the copies number of the ZNF703 gene, and/or (ii) determining the expression of the ZNF703 gene, wherein an increased copies number and/or an over-expression of the ZNF703 gene is indicative of a luminal B tumor; to a kit for diagnosing a breast cancer from the luminal-B subtype in a female including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a method as defined previously, for determining the copies number of the ZNF703 gene, and/or determining the expression of the ZNF703 gene; and to the use of such a kit.

Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.

Abstract: An in vitro method for diagnosing a breast cancer from the luminal-B subtype in a female, includes the steps of analyzing a biological sample from the female by (i) determining the copies number of the ZNF703 gene, and/or (ii) determining the expression of the ZNF703 gene, wherein an increased copies number and/or an over-expression of the ZNF703 gene is indicative of a luminal B tumor; to a kit for diagnosing a breast cancer from the luminal-B subtype in a female including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a method as defined previously, for determining the copies number of the ZNF703 gene, and/or determining the expression of the ZNF703 gene; and to the use of such a kit.

Abstract: A disclosed projection system includes a display that renders a video representing a sequence of original images each having a corresponding frame interval, and one or more viewing device(s). During each frame interval, multiple subimages are displayed that, in some cases, average together to approximate an original image corresponding to that frame interval. The viewing device(s) attenuate each of the subimages by a respective coefficient to synthesize a target image for each frame interval. The system may include additional viewing device(s) that apply attenuation coefficients to the subimages to synthesize a second, different target image for each frame interval. A described projection method includes displaying multiple subimages in each frame interval, and transmitting attenuation coefficients to the viewing device(s).

Abstract: A method for predicting the sensitivity of tumor cells to an anthracycline-based chemotherapy includes determining the differential expression level of a MYBL2 gene in tumors cells. A polynucleotide library is useful to predict the sensitivity of tumor cells to an anthracycline-based chemotherapy and includes a pool of polynucleotide sequences or subsequences thereof wherein the sequences or subsequences correspond substantially to any of the polynucleotide sequences SEQ ID No: 308, SEQ ID No: 309 and/or SEQ ID No: 310 or the complements thereof.

Abstract: A method for diagnosing a myeloid cancer in a subject, includes the step of analyzing a biological sample from the subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID N°2. A kit for diagnosing myeloid cancer in a subject including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method is also described.

Abstract: Method for molecular characterization of a carcinoma including: (i) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a first group determining expression level of the polynucleotide from the first group to differentiate a tumor in which a lymph node has been invaded by a tumor cell from a tumor in which a lymph node has not been invaded by a tumor cell; (ii) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a second group determining expression level of the polynucleotide from the second group to distinguish tumors sensitive to anthracycline from tumors insensitive to anthracycline; (iii) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a third group determining expression levels of the polynucleotide from the third group to classify good and poor prognosis primary breast tumors.

Abstract: The present invention relates to a method for analyzing cancer. e.g., breast cancer including detection of differential expression of at least one of the 16 genes encoding serine/threonine kinases listed in Table 1, or of the 16 genes, and to a polynucleotide library including at least one the 16 genes. This finds use in the development of novel applications, in particular in the development of prognosis or diagnostic of breast cancer or for monitoring the treatment of a patient with a breast cancer.

Abstract: The present invention relates to a method of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer in view of the expression of specific nucleic acid sequences in a biological sample.

Abstract: A disclosed projection system includes a display that renders a video representing a sequence of original images each having a corresponding frame interval, and one or more viewing device(s). During each frame interval, multiple subimages are displayed that, in some cases, average together to approximate an original image corresponding to that frame interval. The viewing device(s) attenuate each of the subimages by a respective coefficient to synthesize a target image for each frame interval. The system may include additional viewing device(s) that apply attenuation coefficients to the subimages to synthesize a second, different target image for each frame interval. A described projection method includes displaying multiple subimages in each frame interval, and transmitting attenuation coefficients to the viewing device(s).

Abstract: The present application relates to gene analysis and, in particular, to gene expression profiling for identifying molecular signature of cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer and studying cancer. More particularly, the application is directed to a method for analyzing differential gene expression associated with cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer comprising detection of upregulation and/or downregulation of a pool of polynucleotide sequences in a cell or tissue sample, said pool corresponding to all or part the polynucleotide sequences, subsequences or complements thereof, of the genes listed in Tables 1, 2 and 3.

Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.

Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.

Abstract: A method for analyzing differential gene expression associated with breast tumor is based on the analysis of the over-expression or under-expression of polynucleotide sequences in a biological sample. The analysis includes the detection of the over-expression of at least one polynucleotide sequence(s), subsequence(s) or complement(s) thereof selected from predefined polynucleotide sequence sets.

Abstract: Differential gene expression associated with histopathologic features of colorectal disease can be performed with nucleic acid arrays. Such arrays can comprise a pool of polynucleotide sequences from colon tissues, and the detection of the overexpression or underexpression of polynucleotide sequences (or subsequences or complements thereof) from this pool can provide information relating to the detection, diagnosis, stage, classification, monitoring, prediction, prevention or treatment of colorectal disease.

Abstract: A method for analyzing differential protein expression associated with histopathologic features of breast disease including detecting overexpression or underexpression of a pool of proteins in breast tissues or cells, the pool including at lease one of a protein set including Afadin, Aurora A, a-Catenin, b-Catenin, BCL2, Cyclin D1, Cyclin E, Cytokeratin 5/6, Cytokeratin 8/18, E-Cadherin, EGFR, ERBB2, ERBB3, ERBB4, Estrogen receptor, FGFR1, FHIT, GATA3, Ki67, Mucin 1, P53, P-Cadherin, Progesterone receptor, TACC1, TACC2, TACC3, Cytokeratin 6, Cytokeratin 18, Ang1, AuroraB, BCRP1, CathepsinD, CD10, CD44, CK14, Cox2, FGF2, GATA4, Hif1a, MMP9, MTA1, NM23, NRG1a, NRG1beta, P27, Parkin, PLAU, S100, SCRIBBLE, Smooth Muscle Actin, THBS1 and TIMP1.

Abstract: The present invention relates to a method for analyzing differential gene expression associated with breast tumor, based on the analysis of the over-expression or under-expression of polynucleotide sequences in a biological sample. The analysis comprises the detection of the over-expression of at least one polynucleotide sequence(s), subsequence(s) or complement(s) thereof selected from predefined polynucleotide sequence sets.